Last reviewed · How we verify
Alginate
At a glance
| Generic name | Alginate |
|---|---|
| Also known as | Gaviscon Lipuid, Gaviscon |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
- The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants (NA)
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- Clinical Registry Collecting Real World Evidence on Wound Care Treatments
- Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU) (NA)
- Accuracy of Digital Mandibular Repositioning in Occlusal Reconstruction for Patients With Disc Displacement (NA)
- Efficacy of a Polyhexanide Biguanide-Based Gel in the Prevention of Biofilm Formation in Pressure Ulcers (EARLY_PHASE1)
- Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alginate CI brief — competitive landscape report
- Alginate updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI